While PARP inhibitors increase the DNA damage load for the HR pathway and inhibit alternative a-EJ pathway, RAD52 inhibitors block the escape route for BRCA-deficient cancer cells through RAD52-dependent mechanism(s) of DNA repair (Figure 4). This evidence concerns the gene PARP1 and cancer.